Abstract-The clinical and radiologic impact of developing neutralizing antibodies (NAbs) to interferon beta (IFN␤) while on this therapy for multiple sclerosis (MS) is assessed. On the basis of Class II and III evidence, it is concluded that treatment of patients with MS with IFN␤ (Avonex, Betaseron, or Rebif) is associated with the production of NAbs (Level A). NAbs in the serum are probably associated with a reduction in the radiographic and clinical effectiveness of IFN␤ treatment (Level B). In addition, the rate of NAb production is probably less with IFN␤-1a treatment than with IFN␤-1b treatment, although the magnitude and persistence of this difference is difficult to determine (Level B). Finally, it is probable that there is a difference in seroprevalence due to variability in the dose of IFN␤ injected or in the frequency or route of its administration (Level B). Regardless of the explanation, it seems clear that IFN␤-1a (as it is currently formulated for IM injection) is less immunogenic than the current IFN␤ preparations (either IFN␤-1a or IFN␤-1b) given multiple times per week subcutaneously (Level A). However, because NAbs disappear in some patients even with continued IFN␤ treatment (especially in patients with low titers), the persistence of this difference is difficult to determine (Level B). Although the finding of sustained high-titer NAbs (Ͼ100 to 200 NU/mL) is associated with a reduction in the therapeutic effects of IFN␤ on radiographic and clinical measures of MS disease activity, there is insufficient information on the utilization of NAb testing to provide specific recommendations regarding when to test, which test to use, how many tests are necessary, or which cutoff titer to apply (Level U).
The development of neutralizing antibodies (NAbs) to proteins administered therapeutically is often associated with a reduction in the biologic actions that these proteins exert. It is therefore surprising that the clinical and radiographic impact of NAbs to interferon beta (IFN␤) in the treatment of multiple sclerosis (MS) is controversial. This assessment evaluates the clinical and radiographic impact of NAbs in this setting and considers some of the difficulties in this research area that may explain the ongoing controversy. In this regard, it is useful for readers to appreciate the complexity of this particular biologic system. [1] [2] [3] [4] [5] [6] [7] [8] [9] Thus, a brief overview of IFN biology is provided in the supplementary material to this as-sessment (available at www.neurology.org). The questions posed by this assessment are as follows: 1) Once NAb-positivity has developed in an individual patient, does this state persist? 2) Are NAbs to IFN␤ associated with a reduced effectiveness in IFN␤-treated patients with respect to the activity or the severity of MS (measured either clinically or radiographically)? 3) Does the prevalence of NAbpositivity (i.e., the seroprevalence) differ between the different IFN␤ products?
Methods. A panel of neurologists analyzed the evidence relating to NAbs using a literature search with the key words antibodies and interferon beta. We used the MEDLINE database from 1966 to 2005. In addition, the reference lists of the articles identified were reviewed to identify articles not found by the computer search. Using these methods we identified 627 articles. Twentyseven articles in the English language reporting clinical or radiographic outcomes in both antibody positive and antibody negative patients were reviewed. The entire panel classified the level of evidence provided by each article. Several studies were classified as providing Class II evidence (table 1) , despite a randomized placebo-controlled trial design (RCTs). This is because evidence associated with NAb status is always post hoc and because patients can never be randomized with respect to their ultimate NAb status. Therefore, one can never exclude the possibility that there are patient-specific factors, which both predispose certain patients to the development of NAbs and, in an unrelated manner, make them either more or less susceptible to MS attacks. If so, this will make NAbs artificially appear to increase or decrease the MS attack rate, underscoring the fact that evidence of an association cannot prove causation.
Detecting and measuring antibodies to IFN␤. Antibodies to IFN␤ ultimately develop in many IFN␤-treated patients.
14-41 Two classes of antibodies are recognized. Binding antibodies (BAbs) may or may not interfere with IFN␤ function while neutralizing antibodies (NAbs) interfere with IFN␤ function in vitro, presumably by altering (or blocking) binding to the IFN␣/␤ receptor. Conceptualized in this manner, NAbs are a subset of the BAbs. Nevertheless, this conception may be simplistic. For example, in a recently presented study, 42 some NAb-positivity was measured in patients who were BAb-negative. Because only the BAb assay is specific for IgG, and if there is not some technical reason for this result, this suggests that some measured NAb-positivity may not be antibody mediated.
IFN␤ antibodies can be detected through 28, [43] [44] [45] [46] binding assays, including enzyme-linked immunosorbent assays (ELISAs) and radio-immuno-precipitation assays (RIPAs), that measure all BAbs. 28, 46 Two assays specifically measure NAbs. The cytopathic effect (CPE) assay measures a reduction in the amount of IFN␤-induced inhibition of virally mediated cell lysis. 43 By contrast, the MxA assay measures a reduction (either in vitro or in vivo) in the amount of IFN␤-induced MxA protein (or mRNA) synthesis. 44, 45 Both the CPE and the MxA assays depend upon assay conditions and require standardization. Either assay had a 2 to 4% false positive rate as judged by the other in a clinical trial setting. 32 For cost reasons, antibodies are often measured using a two-step method, in which sera is screened by a binding assay for the presence of BAbs, and, if positive, assayed for NAbs using the CPE or MxA methods. 28 It is possible that NAbs attach to the receptor-binding region of the IFN␤ molecule, whereas non-NAbs attach to less critical epitopes. Some BAbs seem to have little measurable impact on IFN␤ activity (as it is measured by current NAb assays) although BAbs still might lower serum IFN␤ levels by increasing IFN␤-clearance through the reticuloendothelial system. Despite the fact that in vivo IFN␤ activity might be affected in these alternative ways, NAbs are associated with attenuation of many IFN␤-induced proteins, including IFN␤-specific proteins such as TRAIL (see supplementary data on the Neurology Web site at www.neurology.org).
47-49
Determining NAb-positivity. Varying definitions of NAbpositivity make comparisons between studies problematic. Many use an arbitrary titer of 20 neutralizing units (NU) per milliliter as the cutoff value for NAb-positivity, although there is evidence that higher titers (e.g., more than 100 or 200 NU/mL) are more likely to have an impact on clinical parameters and biomarkers than lower titers. 29, 31, 32, 41, 48, 49 Additionally, some patients revert from NAb-positive to NAb-negative status over time. Reversion is more likely with NAb titers of less than 200 NU/mL, although it can happen at titers as high as 3,094 NU/mL. 31, 35 In analyzing the effects of NAbs, some authors have used the ever positive, always positive method, in which patients who were ever NAb-positive are compared to persistently NAb-negative subjects. 19, [21] [22] [23] [24] [25] Other studies use the so-called once positive, always positive method, in which only observations after the patient has become NAb-positive (often defined as two consecutive positive tiers) are compared to observations in NAb-negative subjects. [14] [15] [16] 20, 29, 31 Each of these methods fails to account for subjects who revert to NAb-negative status after becoming NAb-positive. In a reanalysis of the IFN␤-1b (Betaseron) trial, 51% to 65% of the NAb-positive patients in the high-dose arm reverted to NAb-negative status at some time. 32 Inevitably, clinical attacks occurring during a patient's NAb-negative periods will be attributed inappropriately to the attack rate in the NAb-positive group. Attempts to minimize such errors include measuring NAbs every 3 months and assuming that the switch in NAb status occurred at the time of NAb measurement, 29, 32 or measuring NAbs at 12-month intervals, presuming subjects were at the measured NAb status from 6 months preceding to 6 months following the NAb determination. 30 Recently, in the so-called interval analysis method, investigators assumed subjects were NAb-positive throughout a 6-month interval if they were positive (by a single determination) at the end of the interval. 38 Unfortunately, each of these analysis methods will combine data from both NAb-positive and NAb-negative periods when they are used in a population of patients who are spontaneously switching their NAb status. This will be an even greater problem if there is a delay in the clinical impact of NAbs, as suggested by some authors. Most importantly, however, these alternative methods have not particularly clarified the clinical impact of NAbs when compared directly to either the once positive, always positive or the ever positive, always positive methods. 29, 30, 32, 35 Due to small numbers (table 1), data often lack the statistical power to detect a convincing effect of NAbs. [14] [15] [16] [17] [18] 25, 37, 38, 40, 41 Sometimes, two different treatment arms of a trial are combined in an attempt to increase statistical power. 35, 38 Because such analyses are done post hoc, they increase the likelihood of bias. Unfortunately, because so little post-marketing information has been acquired, we continue to lack studies with sufficient statistical power to address many important NAb questions, despite more than 150,000 patients being on IFN␤ therapy worldwide.
Analysis of the evidence.
General considerations regarding the evidence. As an example of the potential impact of NAbs on IFN␤ efficacy, 38% of patients in the high-dose arm of the phase III IFN␤-1b (Betaseron) trial 10,14,16 became NAb-positive (defined as two consecutive positive titers of Ն20 NU/mL 3 months apart and also as once positive, always positive) after 2 years. When NAb-positive and NAb-negative patients were analyzed separately, the NAb-positive patients seemed to have attack rates similar to placebo-treated patients. 10 There are several reasons why such an observation might not be interpreted as easily as it might seem at first glance and also why, in general, relating NAb titers to outcome (either positive or negative) is fraught with problems.
First, as discussed earlier, many of the patients analyzed in this fashion did not become NAb-positive until late in the course of the trial when attack rates had spontaneously declined in all treatment groups. 32 Even among those patients who became NAb-positive in this study, a large percentage ultimately became NAb-negative, at least temporarily. 32 Both of these circumstances confound any straightforward interpretation of the data.
Second, the relationship of the IFN␤ activities neutralized by NAbs to the mechanisms whereby IFN␤ exerts its therapeutic effects in MS is uncertain. Although it seems reasonable to expect that interference with one receptor-mediated action would translate to an impact on all such actions, this may not be the case. For example, as noted in the supplementary data (www.neurology.org), despite the fact that IFN␣ and IFN␤ bind to the same receptor, each molecule has a distinct pattern of downstream biologic effects. 2, 5 Consequently, receptor binding could be distorted by NAbs in such a way that some functions, but not others, are impacted.
Third, antigen-antibody complexes (and thus the mere presence of BAbs with or without NAbs) can also modulate immune functions. These effects will be independent of the receptor-mediated functions of IFN␤ and would be expected to be most conspicuous in patients with high antibody titers.
Fourth, because of the marked intersubject variability in both the clinical course of MS and the response to administered IFN␤, and because IFN␤ has only a modest effect on clinical outcomes, it will be very difficult to establish conclusively a deleterious effect of NAbs on clinical outcomes using small datasets. To do this will require the study of large numbers of NAb-positive patients although, with over 150,000 patients on therapy worldwide, these numbers should be easily achievable.
Once NAb-positivity has developed in an individual patient, does this state persist? Studies of the natural history of NAbs in IFN␤-treated patients suggest that the NAb-positive state is often transient. For example, in a subset of patients from the original IFN␤-1b trial, almost 80% of NAb-positive patients had reverted to NAb-negative status after 8 years 12 despite continued IFN␤-1b therapy. Also, as mentioned earlier, 51 to 65% of NAb-positive patients in the high dose arm of this trial reverted to NAb-negative status (at least temporarily) within the first 3 years. 32 Similarly, in a recent study of 23
NAb-positive IFN␤-1b treated patients who were switched to IFN␤-1a, only 6 out of 20 (30%) and 3 out of 14 (21%) remained NAb-positive after 2 and 5 years. 50 Also, the reversion rate from NAb-positive to NAb-negative status was 50% in a small Italian study after 3 to 4 years 41 and it was 54% after 3 years in the North American trial of IFN␤-1b in SPMS. 33 It seems that, despite continued treatment with IFN␤, the majority of NAb-positive patients will ultimately revert to NAb-negative status after 3 to 8 years of therapy. Nevertheless, the actual rate of NAb disappearance is difficult to define precisely because the data from long-term studies may be biased from the potential impact of selective drop-out (i.e., patients doing poorly on therapy will stop). This apparently increased tolerance to IFN␤ over time may be molecule specific. In a Danish study of 455 patients, the authors reported that the cumulative probability of reverting to definitely NAb-negative status (i.e., two consecutive NAb-negative titers) in IFN␤-1b (Betaseron) treated patients was 57% after 42 months (CI ϭ 0.43 to 0.71) compared to only 19% (CI ϭ 0.07 to 0.30) in IFN␤-1a (Rebif) treated patients over the same time period. 13 Because most patients who revert to NAb-negative status tend to have titers of 100 NU/mL or less 29, 32, 38, 41, 48, 49 such a difference might reflect higher NAb-titers to IFN␤-1a compared to IFN␤-1b. 51 
Are NAbs to IFN␤ associated with an increase in the activity or the severity of MS (measured either clinically or radiographically) in IFN␤-treated patients?
Persistently high NAb titers to IFN␤ seem likely to have an impact on the clinical and radiographic efficacy of IFN␤, particularly as assessed by MRI (table 1). The effect of NAbs on clinical measures (especially measures of disease severity such as confirmed Expanded Disability Status Scale progression) is less convincing, although, even for clinical measures of disease activity (i.e., attack rate), the majority of studies greater than 2 years in duration reported a higher attack rate in NAb-positive compared to NAb-negative patients ( 33 a NAb-associated increase in relapse rate was found (p ϭ 0.05 to 0.01).
Impact of NAb-positivity on clinical decisions. Despite this evidence, however, it is still unclear whether NAbs eliminate or merely attenuate the effect of IFN␤. Some individuals can have an apparently excellent response to IFN␤ despite having very high NAb titers. For example, in an NIH study of IFN␤-1b, 3 of the 11 patients with NAbs had both titers Ͼ400 NU/mL (including the patient with the second highest NAb titer of 1044 NU/mL) and a greater than 90% suppression of MRI activity over the 36 months following the start of IFN␤-1b. 31 In a recent bioactivity study 52 the authors reported that, despite a marked reduction of the normalized ratio (NR) for in vivo IFN␤-induced MxA production, the NR was still greater than the normal mean of 1.0 in most (82%) of the NAb-positive patients and, in over half (65%), the NR was more than three times normal even with NAb-titers up to 800 NU/mL. 52 Thus, although the IFN␤ effect on MxA was attenuated by NAbs, it was not completely eliminated in most patients. 52 Because it is unknown whether such a low level of MxA induction is associated with continued clinical benefit, it is also unknown whether it would be wise to switch a NAb-positive patient to a noninterferon when they are otherwise clinically well. Indeed, because of our uncertainty about the relationship of MxA induction to the mechanisms of IFN␤ benefit, because of the variability of the clinical data (table 1) , and because there is persistent MxA mRNA expression or MxA induction in some persistently NAb-positive individuals, 48, 49, 52 this course of action cannot be recommended. In a NAb-positive patient doing poorly, an alternative therapy should be considered, although such a course of action should probably be considered anyway, regardless of the patient's NAb status. Because NAb-status might influence the choice of subsequent therapy, well standardized and easily accessible methods for NAb measurement should be available to practicing clinicians. Nevertheless, a cautious interpretation by treating neurologists (considering both clinical and probably also MRI data) is necessary.
It is also uncertain whether the apparently deleterious effect of NAbs is offset by the improved efficacy reported with high-dose (more frequently administered) IFN␤. 8 There are only two randomized headto-head comparative trials which might conceivably answer such a question. These are the 63-week EVIDENCE trial, 26, 27 which provides Class I comparative data for both clinical and MRI outcomes, and the 2-year Independent Comparison of Interferon (INCOMIN) trial, 25 which provides Class I comparative data for MRI outcomes and Class III data for clinical outcomes. Both trials, particularly EVIDENCE, are too short to provide a complete answer in view of the dynamics of NAb-positivity discussed earlier. In both trials, NAb-positive patients (defined as positive after a single positive titer of more than 20 NU/mL) in the high-dose (more frequent) IFN␤ arms had lower relapse rates and less MRI activity than the arm receiving low-dose (once weekly) IFN␤ regardless of their NAb status. [25] [26] [27] 39 Therefore, within the first 2 years of treatment, the available evidence favors using the more effective therapy, even if this therapy is associated with a greater seroprevalence of NAbs. Whether the relative advantage of high-dose (more frequently administered) therapy is sustained beyond 2 years is unknown, but any such consideration of long-term impact must estimate and take into account both the magnitude of the NAb-effect and the probability of (and time course for) the spontaneous disappearance of NAbs, which occurs in many patients. 12, 13, 25, 31, 32, 50 Does the rate of NAb production differ between the different IFN␤ products? Prevalence data for NAbs (table 2) is confounded by nonuniform definition of the NAb-positive state and by differences in the assays used. In the Multiple Sclerosis Collaborative Research Group (MSCRG) trial of IFN␤-1a (Avonex), 22% of patients developed NAbs (defined as always positive on the basis of a single titer Ն20 NU/mL) after 2 years of therapy. 17, 18, 28 By contrast, using a newly formulated product, NAbs have generally been found in 7% or less of the IFN␤-1a treated patients. 25, 26, 28, [37] [38] [39] [40] [41] 48, 53 The reason for the difference in seroprevalence between formulations is unknown and demonstrates that efficacy for reformulated products requires a clinical study, not merely an inference from studies using previous formulations.
The seroprevalence of NAbs IFN␤-1b seems higher than with IFN␤-1a (table 2) . 10, 14, 16, 25, 28 However, in a recent survey of 6,698 patients with MS on IFN␤-1b therapy, 54 the seroprevalence of NAbs (defined as a single positive test with a titer Ն20 NU/mL) in two clinically deteriorating cohorts (21% in North America and 28% in Europe) was significantly lower (p Ͻ 10
Ϫ28
for North America and p Ͻ 10 11 for Europe) compared to NAb seroprevalence in an unselected cohort (37% in Australia). Although these unexpected results raise serious questions about any posited connection between NAb-positivity and reduced efficacy, the findings need replication in a more controlled setting before any strong conclusions can be drawn.
With respect to the effect of dose on seroprevalence, two studies demonstrated greater NAbpositivity among low-dose than high-dose arms.
19,21-24
A follow-up trial of placebo patients re-randomized to low or high dose IFNbeta-1a did not confirm this result (table 2) . To further confuse matters, the EVI-DENCE trial found NAb-positivity in 25% of highdose Rebif-treated patients after 1 year, 26 ,27 a number almost double that in earlier placebocontrolled trials. 19, [21] [22] [23] [24] By contrast, in the European dose-comparison study of IFN␤-1a IM, 37,38 the 60-g dose resulted in almost three times the seroprevalence of NAbs compared to the 30-g dose. Despite these conflicting observations, it seems that IFN␤-1a is probably less immunogenic than IFN␤-1b, especially when administered IM. This could be the result of molecular structure. IFN␤-1a is glycosylated, which may reduce its immunogenicity compared to the non-glycosylated IFN␤-1b. [55] [56] [57] Also, if IFN␤-1b forms aggregates, this may increase immunogenicity. Possibly, differences in IFN␤ solubility (caused by the different physical properties of the molecules) or the subcutaneous route might predispose to NAb formation. Regardless, the randomized EVIDENCE trial, 26, 27 which found a marked difference in NAb prevalence between Avonex and Rebif (2% and 25%), indicates that the dose, the formulation, the route, or the frequency of IFN␤-1a administration make an important difference.
Conclusions. 1. Treatment of MS with IFN␤
(Avonex, Betaseron, or Rebif) is associated with the production of NAbs to the IFN␤ molecule (Level A). n ϭ total number of IFN␤-treated patients studied in one or more of the listed dosage arms. Numbers rounded to the nearest 1%.
* Data from a differently formulated product from that which is currently available. 2. It is probable that the presence of NAbs, especially in persistently high titers, is associated with a reduction in the radiographic and clinical effectiveness of IFN␤ treatment (Level B).
3. It is probable that the rate of NAb production is less with IFN␤-1a treatment compared to IFN␤-1b treatment (Level B). However, because of the variability of the prevalence data, and because NAbs disappear in the majority of patients even with continued treatment (especially in those with low-titer NAbs), the magnitude and persistence of any difference in seroprevalence between these forms of IFN␤ is difficult to determine.
4. It is probable that the seroprevalence of NAbs to IFN␤ is affected by one or more of the following: its formulation, dose, route of administration, or frequency of administration (Level B). Regardless of the explanation, it seems clear that IFN␤-1a (as it is currently formulated for IM injection) is less immunogenic than the current IFN␤ preparations (either IFN␤-1a or IFN␤-1b) given multiple times per week subcutaneously (Level A). Because NAbs may disappear in many patients with continued therapy, the persistence of this difference is difficult to determine (Level B).
5. Although the finding of sustained high-titer NAbs (Ͼ100 to 200 NU/mL) has been associated with a reduction in the therapeutic effects of IFN␤ on radiographic and clinical measures of MS disease activity, there is insufficient information on the utilization of NAb testing to provide specific recommendations regarding when to test, which test to use, how many tests are necessary, and which cutoff titer to apply (Level U).
Recommendations for future research. 1. In order to incorporate NAb testing into clinical practice, future research must specifically address issues such as the assay system applied and the stratification of risk for losing IFN␤-efficacy based on the degree of test abnormality. Despite this need for further research, much is already known. NAbs generally develop between 6 and 24 months after the onset of therapy, and if NAbs have not developed by this time, they are unlikely to develop in the future. Newer methods of analysis (e.g., measuring the IFN␤-induced in vivo production of MxA protein or measuring the amount of IFN␤-induced MxA-mRNA expression) may offer more reliable test results. The utility, sensitivity, and specificity for each of these newer techniques for characterizing the in vivo effects of IFN␤ (either in the presence of NAbs or between individuals at baseline) and correlating these changes (or between-subject differences) in the bioactivity of IFN␤ with its subsequent clinical and radiographic actions must be determined.
2. The methods of NAb measurement need to be standardized in order to facilitate cross-trial comparisons. Patients with persistent NAb titers of more than 200 NU/mL, those with persistent lower titers, and those who change status during the course of a trial need to have their clinical and MRI statuses analyzed separately, and only from the time of their first NAb-positive test result. These patient-groups should be compared to persistently NAb-negative patients (adjusted to the time at which the comparator group first became NAb-positive). The effects of NAbs in patients using different products or different doses of IFN␤ need to be analyzed separately.
3. Future clinical trials need to include a longterm ascertainment of NAb status and its clinical impact.
4. Future clinical trials need to include a determination of IFN-responsiveness in individuals at study onset in order to link the biologic activity in both NAb-positive and NAb-negative groups with clinical and radiographic outcomes.
5. Because of the small number of NAb-positive patients generally available in RCTs, and because patients cannot be randomized with respect to their ultimate NAb status (e.g., table 1), conclusive data will need to be compiled from large-scale postmarketing surveys. The pharmaceutical industry and the physician community need to work together to acquire and share postmarketing surveillance data so as to characterize accurately the prevalence, persistence, and consequence of NAbs.
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